Welcome to our dedicated page for Sino Biopharmaceutical news (Ticker: SBHMY), a resource for investors and traders seeking the latest updates and insights on Sino Biopharmaceutical stock.
The news feed for SINO BIOPHARM UNSP/ADR (SBHMY) highlights public announcements and developments associated with Sino Biopharmaceutical Limited and its related entities. Recent coverage focuses on clinical progress and regulatory milestones in pain management and oncology, reflecting the company’s involvement in innovative pharmaceutical research.
One key news theme is the advancement of TRD205, a first-in-class, highly selective angiotensin II type 2 receptor (AT2R) antagonist developed by Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited. News reports describe TRD205 entering Phase II clinical development for chronic post-surgical neuropathic pain, following Phase I trials in healthy Chinese volunteers and clinical trial approvals from both the U.S. Food and Drug Administration and China’s National Medical Products Administration. Articles detail the drug’s non-opioid mechanism, its focus on peripheral pain pathways, and the public health need it aims to address.
Another recurring topic is oncology, particularly updates on Penpulimab monoclonal antibody, an anti PD-1 monoclonal antibody drug co-developed by Akeso, Inc. and Sino Biopharmaceutical Limited. News items cover Penpulimab’s marketing approval in China for relapsed or refractory classic Hodgkin's lymphoma after at least second-line systemic chemotherapy, along with trial design, response rates and safety data that supported approval.
By following SBHMY news, readers can track clinical trial milestones, regulatory decisions, and collaboration updates related to TRD205 and Penpulimab. This page provides a centralized view of press releases and public statements that shed light on the development trajectory and therapeutic focus areas connected to Sino Biopharmaceutical Limited.
Akeso, Inc. announced that its co-developed anti PD-1 monoclonal antibody, Penpulimab, received marketing approval from China's NMPA for treating relapsed or refractory classic Hodgkin's lymphoma. This approval follows a pivotal trial showing an impressive objective response rate of 89.4% and a complete response rate of 47.1%. The drug's safety profile indicates low serious adverse events, with a median treatment duration of 14.8 months. Akeso is pursuing additional approvals for Penpulimab for various cancers in China and the U.S., highlighting its potential in oncology.
FAQ
What is the current stock price of Sino Biopharmaceutical (SBHMY)?
What is the market cap of Sino Biopharmaceutical (SBHMY)?
